Dosage and administration
rub hands vigorously with the towelette for about 15 seconds pay particular attention to nails and interdigital spaces no watering or toweling are necessary
rub hands vigorously with the towelette for about 15 seconds pay particular attention to nails and interdigital spaces no watering or toweling are necessary
Drug Facts
| Active ingredients | Purposes |
|---|---|
| Chlorhexidine gluconate solution 0.5% w/w | Antiseptic |
| Isopropyl alcohol, 70% w/w | Antiseptic |
For external use only
Flammable: keep away from fire or flame.
Do not use
Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.
castor oil, glycerin, purified water
1-800-843-8497
NDC 0234-0587-17
HIBISTAT®
(0.5% Chlorhexidine
Gluconate solution
70% isopropyl alcohol w/w)
Healthcare Personnel Hand Antiseptic
HIBISTAT® provides rapid bactericidal action and has
a persistent antimicrobial effect against a wide range
of microorganisms.
WARNING: For external use only
Flammable: Keep away from fire or flame.
FOR PROFESSIONAL USE ONLY.
MÖLNLYCKE®
HEALTH CARE
1 Hand Antiseptic Wipe (5mL)
Distributed by Mölnlycke Health Care US, LLC.,
Norcross GA 30092

| Class | Version | Type | Effective |
|---|---|---|---|
| CHLORHEXIDINE Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 6c13b22c-b3ba-4127-b768-0132dd5ab0d1 | Product name | 1 | 20230829 |
| bb6d6c68-649d-4e6d-a1f6-603d969c8f68 | Product name | 1 | 20160303 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 0234-0587-17 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-04de-f424-e053-dadaa90a57ce | HIBISTAT ® (0.5% Chlorhexidine Gluconate solution 70% isopropyl alcohol w/w) |
| 0234-0587-27 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-04de-f424-e053-dadaa90a57ce | HIBISTAT ® (0.5% Chlorhexidine Gluconate solution 70% isopropyl alcohol w/w) |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 0234-0587-17 | Hibistat | 5 mL in 1 PACKET | SOLUTION | 5 | 1 | |
| 0234-0587-17 | Hibistat | 50 in 1 CARTON | SOLUTION | 50 | 1 | |
| 0234-0587-27 | Hibistat | 15 in 1 CARTON | SOLUTION | 15 | 1 | |
| 0234-0587-27 | Hibistat | 5 mL in 1 PACKET | SOLUTION | 5 | 1 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0234-0587-17 | EA - Each | 0234-0587 | d70e2392-3ff1-4828-8894-0174ef06e0a8 | 1 | 2012-07-24 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Chlorhexidine gluconate | ACTIVE INGREDIENT | MOR84MUD8E | 1 | |
| Isopropyl alcohol | ACTIVE INGREDIENT | ND2M416302 | 1 | |
| Chlorhexidine | ACTIVE MOIETY | R4KO0DY52L | 1 | |
| Isopropyl alcohol | ACTIVE MOIETY | ND2M416302 | 1 | |
| Castor Oil | INACTIVE INGREDIENT | D5340Y2I9G | 1 | |
| Glycerin | INACTIVE INGREDIENT | PDC6A3C0OX | 1 | |
| Water | INACTIVE INGREDIENT | 059QF0KO0R | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 0234-0587 | 0234-0587-17, 0234-0587-27 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| Chlorhexidine gluconate | MOR84MUD8E | ACTIB |
| Isopropyl alcohol | ND2M416302 | ACTIB |
| Castor Oil | D5340Y2I9G | IACT |
| Glycerin | PDC6A3C0OX | IACT |
| Water | 059QF0KO0R | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| Glycerin | GLYCERIN | PDC6A3C0OX | TABLET / PERIODONTAL | 0.53 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SYSTEM / IONTOPHORESIS | 168.1 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SUSPENSION/ DROPS / OPHTHALMIC | 2.5 %w/v | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SUPPOSITORY / VAGINAL | 227.9 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION/ DROPS / OPHTHALMIC | 12 mg | ||
| Castor Oil | CASTOR OIL | D5340Y2I9G | TABLET, EXTENDED RELEASE / ORAL | 23.27 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SUSPENSION / ORAL | 26208 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | JELLY / VAGINAL | NA | ||
| Castor Oil | CASTOR OIL | D5340Y2I9G | OINTMENT / TOPICAL | 14.9 %w/w | ||
| Castor Oil | CASTOR OIL | D5340Y2I9G | EMULSION / OPHTHALMIC | 32 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / DENTAL | 15 %w/v | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | GEL / OPHTHALMIC | 0.88 %w/w | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | DROPS / NASAL | 10 mg/1ml | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | CONCENTRATE / ORAL | 1800 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION/ DROPS / AURICULAR (OTIC) | 25 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SPRAY / NASAL | 22.3 mg/1ml | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | INJECTION / INTRAMUSCULAR | 450 mg | ||
| Castor Oil | CASTOR OIL | D5340Y2I9G | INJECTION / INTRAMUSCULAR | 885 mg | ||
| Castor Oil | CASTOR OIL | D5340Y2I9G | GRANULE, FOR SUSPENSION / ORAL | 128 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | INJECTION / INTRADERMAL | 1.6 %w/v | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | FILM, EXTENDED RELEASE / BUCCAL | 34 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | GEL / TRANSDERMAL | 500 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | LOTION / TOPICAL | 3990 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | TABLET / ORAL | 42 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / TOPICAL | 1971 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SUSPENSION / AURICULAR (OTIC) | 0.05 %w/w | ||
| Castor Oil | CASTOR OIL | D5340Y2I9G | SPRAY / NASAL | NA | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | INJECTION / INTRAVENOUS | 33750 mg | ||
| Castor Oil | CASTOR OIL | D5340Y2I9G | GEL / NASAL | 429 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / ORAL | 32400 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | CLOTH / TOPICAL | 0.05 mg/mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | AEROSOL / TOPICAL | 3 %w/w | ||
| Castor Oil | CASTOR OIL | D5340Y2I9G | TABLET, COATED / ORAL | 0.9 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | FILM, EXTENDED RELEASE / TRANSDERMAL | 306.2 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SUPPOSITORY / RECTAL | 440 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | INJECTION / SUBCUTANEOUS | 450 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | JELLY / TOPICAL | NA | ||
| Castor Oil | CASTOR OIL | D5340Y2I9G | TABLET, FILM COATED / ORAL | 15.29 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | DROPS / ORAL | 300 mg/1ml | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | EMULSION / INTRAVENOUS | 2.2 %w/v | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / OPHTHALMIC | 6 %w/v | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | CAPSULE, LIQUID FILLED / ORAL | 185 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SYSTEM / TOPICAL | 18144 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | INJECTION, SOLUTION / INTRAVENOUS | 15 %w/v | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | PASTE / DENTAL | 20 %w/w | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SUSPENSION, EXTENDED RELEASE / ORAL | 2000 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | DOUCHE / VAGINAL | 1 %w/w | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SPONGE / TOPICAL | 2 %w/w | ||
| Castor Oil | CASTOR OIL | D5340Y2I9G | TABLET, DELAYED RELEASE / ORAL | 0.01 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | PASTE, DENTIFRICE / DENTAL | 18 %w/w | ||
| Castor Oil | CASTOR OIL | D5340Y2I9G | CAPSULE / ORAL | 1.04 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / RESPIRATORY (INHALATION) | 5 %w/w | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | LIQUID / TOPICAL | 2.5 %w/w | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | INJECTION, SUSPENSION / SUBCUTANEOUS | 1.6 %w/v | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | TABLET, EXTENDED RELEASE / ORAL | 7 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SUSPENSION/ DROPS / ORAL | 750 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | GEL / TOPICAL | 500 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SOAP / TOPICAL | 0.76 %w/w | ||
| Castor Oil | CASTOR OIL | D5340Y2I9G | TABLET / ORAL | 17 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | INJECTION, EMULSION / INTRAVENOUS | 24100 mg |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N018300-001 | HIBISTAT | CHLORHEXIDINE GLUCONATE | 0.5% | SOLUTION / TOPICAL | RLD, RS, Approved before 1982 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N018300-001 | HIBISTAT | 0.5% | SOLUTION / TOPICAL | RLD, RS, Approved before 1982 | 84e616aacf4f… | ||
| 2026-08-18 06:07:40 | 2026-07 | N018300-001 | HIBISTAT | 0.5% | SOLUTION / TOPICAL | RLD, RS, Approved before 1982 | caaa826d4ba7… | ||
| 2026-02-19 14:30 UTC | 2026-02 | N018300-001 | HIBISTAT | 0.5% | SOLUTION / TOPICAL | RLD, RS, Approved before 1982 | 011fe1cb6892… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N018300-001 | HIBISTAT | 0.5% | SOLUTION / TOPICAL | RLD, RS, Approved before 1982 | 31067a03dcf5… | ||
| 2025-08-23 18:47 UTC | 2025-08 | N018300-001 | HIBISTAT | 0.5% | SOLUTION / TOPICAL | RLD, RS, Approved before 1982 | 6a471c1ec25d… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N018300-001 | HIBISTAT | 0.5% | SOLUTION / TOPICAL | RLD, RS, Approved before 1982 | fd3edfee7708… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N018300-001 | HIBISTAT | 0.5% | SOLUTION / TOPICAL | RLD, RS, Approved before 1982 | b8a1b40f171c… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N018300-001 | HIBISTAT | 0.5% | SOLUTION / TOPICAL | RLD, RS, Approved before 1982 | 03ed91905a0d… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N018300-001 | HIBISTAT | 0.5% | SOLUTION / TOPICAL | RLD, RS, Approved before 1982 | 2680178bc6a6… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N018300-001 | HIBISTAT | 0.5% | SOLUTION / TOPICAL | RLD, RS, Approved before 1982 | 5bbf6a4d5a75… | ||
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N018300-001 | HIBISTAT | 0.5% | SOLUTION / TOPICAL | RLD, RS, Approved before 1982 | d8e5a09893c0… | ||
| 2024-10-29 15:01 UTC | 2024-10 | N018300-001 | HIBISTAT | 0.5% | SOLUTION / TOPICAL | RLD, RS, Approved before 1982 | d06236e962d9… | ||
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N018300-001 | HIBISTAT | 0.5% | SOLUTION / TOPICAL | RLD, RS, Approved before 1982 | 79d66fd596c7… | ||
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N018300-001 | HIBISTAT | 0.5% | SOLUTION / TOPICAL | RLD, RS, Approved before 1982 | 301d65b070ca… | ||
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N018300-001 | HIBISTAT | 0.5% | SOLUTION / TOPICAL | RLD, RS, Approved before 1982 | 1e350fbaab3a… | ||
| 2024-05-31 18:47 UTC | 2024-05 | N018300-001 | HIBISTAT | 0.5% | SOLUTION / TOPICAL | RLD, RS, Approved before 1982 | 8072bd15b7f6… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N018300-001 | HIBISTAT | 0.5% | SOLUTION / TOPICAL | RLD, RS, Approved before 1982 | 5c6f7cd8ea54… | ||
| 2022-04-08 23:34 UTC | 2022-04 | N018300-001 | HIBISTAT | 0.5% | SOLUTION / TOPICAL | RLD, RS, Approved before 1982 | 5d02ea3f76ae… | ||
| 2022-04-04 05:41 UTC | 2022-04 | N018300-001 | HIBISTAT | 0.5% | SOLUTION / TOPICAL | RLD, RS, Approved before 1982 | 4b0b4de00fa7… | ||
| 2019-12-13 00:20 UTC | 2019-12 | N018300-001 | HIBISTAT | 0.5% | SOLUTION / TOPICAL | RLD, RS, Approved before 1982 | 74a2ff9319b5… | ||
| 2022-03-09 01:35 UTC | 2022-03 | N018300-001 | HIBISTAT | 0.5% | SOLUTION / TOPICAL | RLD, RS, Approved before 1982 | bb7c543d1eb4… | ||
| 2021-12-28 21:50 UTC | 2021-12 | N018300-001 | HIBISTAT | 0.5% | SOLUTION / TOPICAL | RLD, RS, Approved before 1982 | 782e0a99824c… | ||
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N018300-001 | HIBISTAT | 0.5% | SOLUTION / TOPICAL | RLD, RS, Approved before 1982 | 87673890dc5c… | ||
| 2021-03-12 10:30 UTC | 2021-03 | N018300-001 | HIBISTAT | 0.5% | SOLUTION / TOPICAL | RLD, RS, Approved before 1982 | 5aa47cf7b7d7… | ||
| 2020-12-22 03:56 UTC | 2020-12 | N018300-001 | HIBISTAT | 0.5% | SOLUTION / TOPICAL | RLD, RS, Approved before 1982 | 8869cabd3fbd… | ||
| 2020-11-12 02:37 UTC | 2020-11 | N018300-001 | HIBISTAT | 0.5% | SOLUTION / TOPICAL | RLD, RS, Approved before 1982 | c0c555d07b60… | ||
| 2019-12-14 00:12 UTC | 2019-12 | N018300-001 | HIBISTAT | 0.5% | SOLUTION / TOPICAL | RLD, RS, Approved before 1982 | 3f01610625f2… | ||
| 2019-09-15 20:21 UTC | 2019-09 | N018300-001 | HIBISTAT | 0.5% | SOLUTION / TOPICAL | RLD, RS, Approved before 1982 | b00525d2431f… | ||
| 2019-07-19 19:46 UTC | 2019-07 | N018300-001 | HIBISTAT | 0.5% | SOLUTION / TOPICAL | RLD, RS, Approved before 1982 | ea99ee380514… | ||
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N018300-001 | HIBISTAT | 0.5% | SOLUTION / TOPICAL | RLD, RS, Approved before 1982 | 6a51e52b5d6a… | ||
| 2024-02-18 07:12 UTC | 2024-02 | N018300-001 | HIBISTAT | 0.5% | SOLUTION / TOPICAL | RLD, RS, Approved before 1982 | 1c564ffb4f44… | ||
| 2023-12-20 04:57 UTC | 2023-12 | N018300-001 | HIBISTAT | 0.5% | SOLUTION / TOPICAL | RLD, RS, Approved before 1982 | ea1830bbd6c7… | ||
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N018300-001 | HIBISTAT | 0.5% | SOLUTION / TOPICAL | RLD, RS, Approved before 1982 | a72a2bbeb626… | ||
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N018300-001 | HIBISTAT | 0.5% | SOLUTION / TOPICAL | RLD, RS, Approved before 1982 | 9b2671bbb829… | ||
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N018300-001 | HIBISTAT | 0.5% | SOLUTION / TOPICAL | RLD, RS, Approved before 1982 | a67488948f0b… | ||
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | N018300-001 | HIBISTAT | 0.5% | SOLUTION / TOPICAL | RLD, RS, Approved before 1982 | 3f0d92c62455… | ||
| 2023-05-13 08:27 UTC | 2023-05 | N018300-001 | HIBISTAT | 0.5% | SOLUTION / TOPICAL | RLD, RS, Approved before 1982 | 053a50430f4f… | ||
| 2023-01-26 05:58 UTC | 2023-01 | N018300-001 | HIBISTAT | 0.5% | SOLUTION / TOPICAL | RLD, RS, Approved before 1982 | 3bdfa0b2c4d7… | ||
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | N018300-001 | HIBISTAT | 0.5% | SOLUTION / TOPICAL | RLD, RS, Approved before 1982 | 3a93d1ddd44b… | ||
| 2022-10-28 04:53 UTC | 2022-10 | N018300-001 | HIBISTAT | 0.5% | SOLUTION / TOPICAL | RLD, RS, Approved before 1982 | f41ea6bd6efb… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 21c3470f-a2a8-43a4-8b14-7c57e3dd2287 | c6f941d6-527e-4fb8-9581-8532dd84e7a8 | 2011-04-19 | Warnings | 21c3470f-a2a8-43a4-8b14-7c57e3dd2287 c6f941d6-527e-4fb8-9581-8532dd84e7a8 |
Adverse event summaries are temporarily unavailable. Other product information remains available.